Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGS - Delayed Quote USD

Humacyte, Inc. (HUMAW)

Compare
0.3800
+0.0100
+(2.70%)
At close: April 1 at 4:00:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Laura E. Niklason M.D., Ph.D. Founder, President, CEO & Director 899.25k -- 1963
Mr. Dale A. Sander CFO, Chief Corporate Development Officer & Treasurer 704.33k -- 1960
Dr. Heather Ledbetter Prichard Ph.D. Chief Operating Officer 647.78k -- 1978
Ms. Sabrina Osborne GPHR, SPHR Chief People Officer -- -- --
Mr. William John Scheessele Chief Commercial Officer -- -- 1972
Dr. Shamik J. Parikh M.D. Chief Medical Officer 514.72k -- 1973
Mr. Harold Alterson Chief Quality Officer -- -- --
Dr. Yang Cao M.D., Ph.D. Chief Regulatory Officer -- -- 1966

Humacyte, Inc.

2525 East North Carolina Highway 54
Durham, NC 27713
United States
919 313 9633 https://www.humacyte.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
218

Description

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Corporate Governance

Humacyte, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers